Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Pharmacokinetic Characteristics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Hepatic Impairment and in Those With Normal Hepatic Function

NCT07877038 is registered in ClinicalTrials.gov with Chendu DIAO Pharmaceutical Group CO., LTD. as lead sponsor.

NCT NCT07877038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07877038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Pharmacokinetic Characteristics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Hepatic Impairment and in Those With Normal Hepatic Function
Lead sponsor
Chendu DIAO Pharmaceutical Group CO., LTD.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 22, 2026
Completion date
April 7, 2027
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight, t2dm (type 2 diabetes mellitus)